Shifting the Treatment Paradigm: New tools to tackle antimicrobial resistance

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Ongoing innovation is needed to address the growing threat of antimicrobial resistance. The current pipeline is mostly comprised of traditional, small-molecule antibiotics based on existing antibiotic classes.

More and different science will be needed to shift the treatment paradigm from traditional broad-spectrum antibiotics to more focused treatments and novel approaches. These next-generation tools may help improve outcomes for patients by better targeting resistant pathogens and/or reducing the impact on the microbiome. However, novel approaches face important scientific, regulatory and economic challenges that limit investment in their development.

This panel will highlight research and collaborations to develop new tools to tackle AMR and provide an update on efforts to facilitate development and uptake of innovation. While these tools may be years from approval, policy engagement to address identified barriers must begin now.
Endpoints News
Chief Scientific Officer
Soligenix, Inc.
VP, Infectious Diseases Discovery & Chief Scientific Officer, MRL Cambridge Exploratory Center
Merck & Co
Director of the Division of Anti-Infectives
Center for Drug Evaluation and Research (CDER), FDA
Da Volterra